|
M.A. Ustyuzhanina, O.P. Kovtun, S.I. Solodushkin, L.V. Kovalchuk, K.Ya. Zaslavskaya, A.M. Lapshina
Effect of liraglutide therapy on biochemical parameters of carbohydrate metabolism and amylase activity in adolescents with obesity
|
№1 / 2025
|
|
Kurnikova I.A., Chekalina M.S., Ualikhanova A.U.
Optimization of approaches to the treatment of obesity in patients with type 2 diabetes mellitus
|
№8 / 2024
|
|
I.A. Kurnikova, Sh.G. Gulova, S.A. Buturlina, I. Mokhammed
Modern approaches to obesity therapy: efficiency problems
|
№4 / 2022
|
|
E.G. Starostina
New era of type 2 diabetes mellitus therapy: cardiological indications for the use of glucagon-like peptide-1 receptor agonists
|
№4 / 2019
|
|
M.B. Antsiferov, O.M. Koteshkova
EFFICIENCY OF TRIPLE THERAPY USING LIRAGLUTIDE (VICTOZA) - FIRST LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND VISCERAL OBESITY
|
№5 / 2015
|
|
V.I. Kudinov, M.S. Nichitenko, A.I. Chesnikova
THERAPY WITH LIRAGLUTIDE SIGNIFICANTLY IMPROVES GLYCEMIC CONTROL AND HAS POSITIVE IMPACT ON THE CARDIOVASCULAR SYSTEM OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№5 / 2014
|
|
I.Yu.Demidova
The Clinical Advantages Of The First Human Glp-1 Analogue Liraglutide In The Treatment Of Patients With Type 2 Diabetes Mellitus
|
№5 / 2013
|
|
G.R. Galstyan
Multivariable Management Of Type 2 Diabetes Mellitus: What Are Our Current Potentials
|
№16 / 2012
|
|
M.B. Antsiferov
Glucagon-like Peptide-1: From Physiology To Effective Management Of Type 2 Diabetes Mellitus
|
№3 / 2012
|
|
Anciferov M.B.
Type 2 Diabetes Mellitus: Potentials For Achievement Of Optimal Control Without Side Effects
|
№3 / 2011
|
Русский
